Objective: The aim of this study was to systematically evaluate the efficacy of Anluo Huaxian pills combined with nucleotide analogues in treating liver fibrosis resulting from chronic hepatitis B. Method: Medline

Embase

CNKI

CBM

VIP

and Wanfang database were searched to collect Randomized controlled trials (RCT) about cases of treating liver fibrosis resulting from chronic hepatitis B using Anluo Huaxian pills combined with nucleotide analogues. Result: Seven clinical trials were included. The Cochrane Collaboration's method was used for data analysis. Compared with using nucleotide analogues alone

the combination of nucleotide analogues and Anluo Huaxian Wan can significantly improve the degree of liver fibrosis and liver function indices. Combination medication might decrease serum levels of hyaluronic acid(HA) and laminin(LH)

type IV collagen(IV-c)

and in the respect of improving the liver function

combination medication might decrease serum levels of alanine aminotransferase(ALT)

aspartarte aminotransferase(AST). Conclusion: But the differences in the decrease of serum levels of PC-Ⅲ

improvement of splenomegaly and portal hypertension

increase of serum levels of albumin(Alb) was not statistically significant.